IXC-103 is under clinical development by Ixchel Pharma and currently in Phase I for Friedreich Ataxia. According to GlobalData, Phase I drugs for Friedreich Ataxia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IXC-103 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IXC-103 (dimethyl fumarate) is under development for the treatment of mitochondrial myopathy, duchenne muscular dystrophy, Leigh syndrome, Leber’s hereditary optic neuropathy (LHON) and Friedreich ataxia. The drug candidate is a repurposed small molecule. It acts by targeting Nrf2.
Ixchel Pharma overview
Ixchel Pharma is a developer of small-molecule drugs that ameliorate mitochondrial disease. The company’s pipeline products include IXC-103, IXC-201, and IXC-203. The company develops products for the treatment of Friedreich’s ataxia, mitochondrial myopathy, leber’s optic neuropathy, non-alcoholic steatohepatitis and pediatric diabetes. Its IXC-103 is used for inherited treatment of monogenic disease that causes a deficiency of frataxin protein. Ixchel Pharma’s drugs hit the Shc protein target to increase insulin sensitivity and glucose tolerance. It conducts research to identify novel mitochondrial activities and also develops novel chemical entities to treat mitochondrial and metabolic disorders. The company’s NCE’s targets the fundamental cause of the obesity epidemic. Ixchel Pharma is headquartered in Davis, California, the US.
For a complete picture of IXC-103’s drug-specific PTSR and LoA scores, buy the report here.